AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 101 min read$CW

Ogilby Gary A sold $288K of CW

Ogilby Gary A (Senior VP & Corp Controller) sold 399 shares of CURTISS WRIGHT CORP (CW) at $721.95 ($0.29M total) on 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ogilby Gary A
Published Jun 10, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CW
Neutral
high confidence
Mentioned
$CW
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CWNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale details (399 shares at $721.95) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure; it may marginally influence sentiment but is unlikely to drive fundamentals.

03

What to watch

Because it’s explicitly under a pre-arranged 10b5-1 plan, the sale may be mechanically scheduled rather than information-driven.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10; transaction dated 2026-06-09

Background

The article reports a Form 4 insider transaction filed on SEC EDGAR for Curtiss-Wright (CW).

Company-level read

Ticker impact

$CWNeutralHigh confidence
Context

Curtiss-Wright insider (Senior VP & Corp Controller) sold 399 shares on 2026-06-09 at $721.95/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction is likely muted.

Evidence & confidence

The disclosure is a Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Traders sometimes treat clustered insider selling as a sentiment check; if there are other recent insider sales, this could reinforce a bearish tape read.

Key entities

  • issuer
    Curtiss-Wright Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Ogilby Gary A

    Senior VP & Corp Controller who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CW insider trading history →

Related articles

SEP 22
$CWMed

Curtiss-Wright Slides As Investors Question CEO Handoff

Curtiss-Wright (CW) shares fell as investors reacted to a planned leadership transition, with the current COO set to become CEO in 2027. Concerns about strategic continuity and execution risk were raised, despite the company's strong financial position and growth prospects. Quarterly results may be volatile due to cash conversion and supply chain pressures.

tipranks.com1 min
SEP 22
$CWMedAI 8/10

Why is Curtiss-Wright stock sliding today?

Curtiss-Wright stock fell 4.0% after announcing CEO Lynn M. Bamford will transition to Executive Chair, with COO Kevin M. Rayment succeeding in 2027. The change introduced strategic uncertainty, and the stock is near a 52-week low of $544.64, below its high of $808.16. The ex-dividend date is also approaching, adding to the pressure.

investing.com2 min
SEP 15
$CWMed

CW Initiated Coverage by Guggenheim -- Rating Upgraded to Buy

Guggenheim initiated coverage on Curtiss-Wright (CW) with a 'Buy' rating and a $786.00 price target. The stock is currently trading at $551.21, which is 24.3% above its GF Value™ of $443.58, indicating overvaluation. CW has a GF Score™ of 94/100, reflecting strong performance in growth and profitability, but a valuation rank of 5/10. Insider activity shows net selling of $705,928 over the last three months.

gurufocus.com2 min
SEP 6
$CWMed

Curtiss Wright (CW) Wins New Defense Work, Is The Stock Cheap After The Selloff?

Curtiss-Wright (CW) secured $40M in contracts for the U.S. Army's air defense system. Its stock is down 24.3% over 30 days, but up 17.8% over 1 year. Analysts debate its valuation, with some seeing it as undervalued at $566.75, citing strong backlog growth and growth projections. The company trades at a P/E of 38.7x, lower than peers but higher than its own fair ratio of 24.8x.

simplywall.st3 min
SEP 2
$CWMed

Piper Sandler initiates Curtiss-Wright stock at neutral on valuation

Piper Sandler initiated coverage on Curtiss-Wright (NYSE:CW) with a Neutral rating and $665 price target, citing valuation concerns. The company reported Q2 earnings beating EPS estimates but missing on revenue. Curtiss-Wright's order book is up 12% YTD, and it raised its full-year outlook. Piper Sandler notes the stock's multiple expansion and potential overvaluation.

investing.com2 min
SEP 1
$CWHighAI 8/10

Curtiss-Wright reports strong Q2 2026 results and raises full-year guidance across defense, nuclear and industrial markets

Curtiss-Wright reported Q2 2026 sales of $924M, adjusted EPS of $3.72, and adjusted operating margin of 19.4%, all above expectations. The company raised full-year guidance to 8-9% sales growth and 14-16% EPS growth, with free cash flow outlook at $585M-$605M. New orders increased 8% YoY to $1.1B, and backlog reached $4.5B, up 10% from year-end 2025.

bicmagazine.com1 min